HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ: GMAB ) with a Buy and raises the price target from $38 to $40.